Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial).
PD-L1
atezolizumab
immune checkpoint
immunotherapy
rare histologic NSCLC subtypes
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
10
2019
accepted:
24
02
2020
entrez:
1
8
2020
pubmed:
1
8
2020
medline:
1
8
2020
Statut:
epublish
Résumé
Although immunotherapy with immune-checkpoint inhibitors (ICIs) has profoundly changed the therapeutic scenario in the treatment of advanced non-small cell lung cancer (NSCLC), trials of ICIs only enrolled NSCLC patients with common histology. Atezolizumab was approved by the United States Food and Drug Administration (US FDA) in October 2016 and by the European Medicines Agency (EMA) in September 2017 for the treatment of patients with metastatic NSCLC whose disease progressed during or following platinum-containing chemotherapy, regardless of PD-L1 expression. We designed a single-arm, multicenter, two-stage phase II study and plan to enroll 43 patients. The primary objective of the study is to evaluate the antitumor activity of atezolizumab in advanced NSCLC patients with rare histology subtypes. Patients with prior atezolizumab or ICI treatment and with untreated, symptomatic, or progressing brain metastases will be excluded. The primary endpoint is disease control rate. Secondary objectives are toxicity and safety, overall response rate, progression-free survival, overall survival, and time to progression. Diagnosis of NSCLC with rare histology will be confirmed by central pathology revision, and will include: colloid carcinoma, fetal adenocarcinoma, non-endocrine large cell carcinoma, sarcomatoid carcinoma, salivary gland-type tumor, lymphoepithelioma-like carcinoma, and NUT-nuclear protein in testis carcinoma. Archival tumor tissue is required for correlative studies of PD-L1 expression on tumor cells and tumor infiltrating lymphocytes. Therapeutic options in NSCLC with rare histology subtypes, to be assessed in specifically designed trials, are an unmet need. This trial will help elucidate the role of atezolizumab as a viable option in this setting.
Sections du résumé
BACKGROUND
BACKGROUND
Although immunotherapy with immune-checkpoint inhibitors (ICIs) has profoundly changed the therapeutic scenario in the treatment of advanced non-small cell lung cancer (NSCLC), trials of ICIs only enrolled NSCLC patients with common histology. Atezolizumab was approved by the United States Food and Drug Administration (US FDA) in October 2016 and by the European Medicines Agency (EMA) in September 2017 for the treatment of patients with metastatic NSCLC whose disease progressed during or following platinum-containing chemotherapy, regardless of PD-L1 expression.
METHODS
METHODS
We designed a single-arm, multicenter, two-stage phase II study and plan to enroll 43 patients. The primary objective of the study is to evaluate the antitumor activity of atezolizumab in advanced NSCLC patients with rare histology subtypes. Patients with prior atezolizumab or ICI treatment and with untreated, symptomatic, or progressing brain metastases will be excluded. The primary endpoint is disease control rate. Secondary objectives are toxicity and safety, overall response rate, progression-free survival, overall survival, and time to progression. Diagnosis of NSCLC with rare histology will be confirmed by central pathology revision, and will include: colloid carcinoma, fetal adenocarcinoma, non-endocrine large cell carcinoma, sarcomatoid carcinoma, salivary gland-type tumor, lymphoepithelioma-like carcinoma, and NUT-nuclear protein in testis carcinoma. Archival tumor tissue is required for correlative studies of PD-L1 expression on tumor cells and tumor infiltrating lymphocytes.
CONCLUSIONS
CONCLUSIONS
Therapeutic options in NSCLC with rare histology subtypes, to be assessed in specifically designed trials, are an unmet need. This trial will help elucidate the role of atezolizumab as a viable option in this setting.
Identifiants
pubmed: 32733604
doi: 10.1177/1758835920915983
pii: 10.1177_1758835920915983
pmc: PMC7372524
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835920915983Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Onco Targets Ther. 2015 Jun 15;8:1451-7
pubmed: 26109869
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Lung Cancer. 2017 Nov;113:93-101
pubmed: 29110857
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Immunotherapy. 2017 Sep;9(12):955-961
pubmed: 28971752
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
J Thorac Oncol. 2013 Jun;8(6):803-5
pubmed: 23676558
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Eur J Cancer. 2019 Jan;107:124-132
pubmed: 30562710
Lung Cancer. 2015 Jun;88(3):254-9
pubmed: 25862146
Transl Lung Cancer Res. 2016 Dec;5(6):720-726
pubmed: 28149767
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Oncotarget. 2014 Dec 15;5(23):12189-202
pubmed: 25361008
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
Clin Cancer Res. 2020 May 15;26(10):2290-2296
pubmed: 31969335
Case Rep Oncol. 2018 Sep 7;11(3):615-621
pubmed: 30323751